Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
Delayed Toronto Stock Exchange  -  04:00 2022-09-30 pm EDT
5.310 CAD   -0.38%
09/30National Bank Maintains 'Positive View' of Knight Therapeutics Following Investor Meetings
MT
09/23Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies
GL
08/15Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

08/15/2022 | 10:40am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
EURO / BRAZILIAN REAL (EUR/BRL) -0.07% 5.3079 Delayed Quote.-16.26%
EXELON CORPORATION -0.77% 37.46 Delayed Quote.-8.41%
GUD HOLDINGS LIMITED -1.72% 7.41 Delayed Quote.-34.83%
KNIGHT THERAPEUTICS INC. -0.38% 5.31 Delayed Quote.0.19%
NOVARTIS AG 0.81% 75.53 Delayed Quote.-5.92%
All news about KNIGHT THERAPEUTICS INC.
09/30National Bank Maintains 'Positive View' of Knight Therapeutics Following Investor Meeti..
MT
09/23Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of..
GL
08/15Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
MT
08/15Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
GL
08/15Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
GL
08/12National Bank Reviews Knight Therapeutics' 'Strong' Q2 Results
MT
08/12Knight Therapeutics Hold Rating Maintained by Stifel GMP as Q2 Results Beat Forecasts; ..
MT
08/11Knight Therapeutics Reports Q2 EPS C$0.02
MT
08/11Transcript : Knight Therapeutics Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 12, ..
CI
More news
Analyst Recommendations on KNIGHT THERAPEUTICS INC.
More recommendations
Financials
Sales 2022 270 M 197 M 197 M
Net income 2022 -26,5 M -19,3 M -19,3 M
Net Debt 2022 - - -
P/E ratio 2022 -24,3x
Yield 2022 -
Capitalization 608 M 443 M 443 M
Capi. / Sales 2022 2,25x
Capi. / Sales 2023 2,04x
Nbr of Employees 660
Free-Float 69,9%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,31 CAD
Average target price 7,12 CAD
Spread / Average Target 34,1%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
Monica Percario Vice President-Global Scientific Affairs
Daniela Marino Marino Vice President-Legal and Compliance
Sector and Competitors